Nurix Therapeutics (NASDAQ:NRIX) CFO Houte Hans Van Sells 6,284 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 6,284 shares of Nurix Therapeutics stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $12.56, for a total transaction of $78,927.04. Following the transaction, the chief financial officer owned 37,592 shares of the company’s stock, valued at approximately $472,155.52. The trade was a 14.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Houte Hans Van also recently made the following trade(s):

• On Thursday, October 30th, Houte Hans Van sold 3,130 shares of Nurix Therapeutics stock. The stock was sold at an average price of $12.80, for a total transaction of $40,064.00.

Nurix Therapeutics Trading Down 2.5%

Shares of NRIX opened at $12.62 on Tuesday. The stock has a market cap of $970.23 million, a P/E ratio of -4.25 and a beta of 2.30. The company has a 50-day moving average of $9.79 and a two-hundred day moving average of $10.66. Nurix Therapeutics, Inc. has a 12-month low of $8.18 and a 12-month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Thursday, October 9th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.19). The business had revenue of $7.89 million for the quarter, compared to analyst estimates of $16.06 million. Nurix Therapeutics had a negative return on equity of 53.57% and a negative net margin of 292.50%. As a group, analysts forecast that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Y Intercept Hong Kong Ltd acquired a new position in Nurix Therapeutics during the third quarter worth approximately $510,000. Sumitomo Mitsui Trust Group Inc. increased its position in Nurix Therapeutics by 11.9% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,557,479 shares of the company’s stock worth $14,391,000 after purchasing an additional 165,841 shares during the last quarter. SG Americas Securities LLC acquired a new position in Nurix Therapeutics during the third quarter worth approximately $203,000. Nikko Asset Management Americas Inc. increased its position in Nurix Therapeutics by 83.8% during the second quarter. Nikko Asset Management Americas Inc. now owns 1,389,274 shares of the company’s stock worth $15,796,000 after purchasing an additional 633,304 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Nurix Therapeutics by 118.3% during the second quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock worth $73,000 after purchasing an additional 3,475 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on NRIX shares. Piper Sandler cut their target price on shares of Nurix Therapeutics from $35.00 to $32.00 and set an “overweight” rating for the company in a research report on Friday, October 10th. UBS Group cut their price objective on shares of Nurix Therapeutics from $30.00 to $26.00 and set a “buy” rating for the company in a research report on Thursday, July 10th. Needham & Company LLC reissued a “buy” rating and issued a $27.00 price objective on shares of Nurix Therapeutics in a research report on Monday, October 20th. Wall Street Zen lowered shares of Nurix Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, October 11th. Finally, HC Wainwright cut their price target on Nurix Therapeutics from $33.00 to $28.00 and set a “buy” rating for the company in a report on Monday, October 27th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Nurix Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $26.73.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.